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Few issues in risk analysis have generated as
heated controversy as that of how best to
protect children’s health from chemical con-
taminants in the environment. The issue is
not whether to protect children, because few
would argue against protecting children; the
issue is how best to protect them. Insults
that occur during development in utero or
during childhood can have tragic conse-
quences in terms of birth defects and greater
likelihood of disease throughout both child-
hood and adulthood, having great social and
emotional costs. The proportion of birth
defects and other problems attributable to
environmental exposures to chemicals is not
known, but even if that proportion is small,
it could constitute a public health problem
by virtue of the numbers of people affected.
Many are questioning the extent to which
methods used by regulatory agencies to
assess risks from environmental chemicals
are adequate to protect children.
Much of the current concern surround-
ing children’s health and risks from chemicals
in the environment is attributed to the
National Academy of Sciences report
Pesticides in the Diets of Infants and Children
(1). That report concluded that there can be
profound differences between children and
adults, that children may experience quanti-
tatively and qualitatively different exposures
to chemicals than do adults, that children
may be more or less sensitive to chemically
induced toxicity than adults, and that stan-
dard approaches to risk assessment and regu-
lation may not always account explicitly for
potential age-related differences in exposure
and toxicity. The resulting concern that, at
least in some cases, children may not be pro-
tected adequately by current regulatory poli-
cies provided the momentum that led to the
children’s health provisions of the 1996 Food
Quality and Protection Act (2), to President
Clinton’s 1997 executive order, Protection of
Children from Environmental Health Risks
and Safety Risks (3), to establishment of the
U.S. Environmental Protection Agency’s
(U.S. EPA’s) Office of Children’s Health
Protection and Children’s Health Protection
Advisory Committee, and to a renewed
research focus through the U.S. EPA’s volun-
tary children’s Chemical Evaluation Program
and the Child Health grants program admin-
istered by the U.S. EPA and the National
Institute of Environmental Health Sciences.
Although the policy concerns regarding
children’s environmental health risks include
different types of chemical exposures and
different kinds of health effects, an issue of
particular concern is cancer. There is a fear
that chemical exposures during childhood or
in utero could increase cancer incidence both
during childhood and later in life. Reported
increases in rates of brain cancer in children
and of testicular cancer in young men are
cited as evidence that environmental expo-
sures may have a public health impact. The
U.S. EPA’s proposed cancer risk assessment
guidelines have not been ﬁnalized because of
wide disagreement about whether they are
appropriately child protective.
An issue of continuing concern is chil-
dren’s exposures to pesticides. The debate
about the need for an additional 10× 
uncertainty factor to address children’s sensi-
tivity in safety assessments involving pesticide
registrations endures. The need for an addi-
tional 10×  factor in cancer risk assessment has
also been raised. By conventional practice in
the United States, safety assessment generally
involves dividing the highest chemical expo-
sure level that does not cause toxicity accord-
ing to animal tests or human data by
uncertainty or safety factors because people
may be more sensitive to toxicity than labora-
tory animals or than other people. The mag-
nitude of the combination of all of these
factors increases when we have less informa-
tion about a chemical’s toxicity to humans,
reﬂecting a need to be health-protective when
we are uncertain. The current debate addresses
the advisability of making acceptable exposure
limits 10 times more stringent than they
already are, speciﬁcally to protect children.
Our goal in this paper is to articulate
some of the questions that must be addressed
in the context of dose–response assessment to
determine whether an extra 10×  uncertainty
factor is appropriate, necessary, or adequate
to protect children from chemical carcino-
gens or other environmental chemicals.
Comparing Sensitivities
Potential differences in exposures and in
inherent biological susceptibility will affect
the likelihood that a child will experience
risk differently from an adult. Sensitivity to a
risk is thus inﬂuenced by both exposure and
susceptibility. In risk assessment, scaling
exposures on a body-weight basis and using
data on behavior patterns and other factors
that affect exposures (when available) yield
exposure assessments that more accurately
reflect age-related exposure differences.
Accounting for age-related differences in
inherent susceptibility as part of dose–
response assessment is much more complex.
Here we focus on susceptibility issues in
dose–response assessment, not on exposure
issues, and the term “sensitivity” is used to
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Risk-based regulation of chemical exposures from the environment generally relies on assump-
tions about the extent of people’s susceptibility to chemically induced diseases. Those assump-
tions are intended to be health-protective; that is, they err on the side of overstating susceptibility.
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based regulations one-tenth more stringent, unless data are available to refute the assumption that
children are more susceptible than adults. In this paper we highlight some of the questions that
should be addressed in the context of risk assessment to determine whether such increased strin-
gency would accomplish the desired result of improving children’s health. In particular, character-
izing beneﬁts of greater stringency requires more information about dose–response relationships
than is currently available. Lowering regulatory levels has attendant costs but may not achieve
benefits, for example, if the previous level were already below an actual or practical threshold.
Without an ability to understand the potential benefit (or lack thereof) of the additional strin-
gency, an appropriate consideration of beneﬁts and costs is not possible. Key words: age, carcino-
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CHILDREN’S HEALTH
Commentarymean the impact that differences in suscepti-
bility have on risk.
Concern about the appropriateness of an
additional 10×  factor to account for chil-
dren’s sensitivity arises for several reasons.
Some authors have suggested that interindi-
vidual variation in susceptibility can exceed
10× , so a factor of 10 is not protective
enough (4). Others suggest that an addi-
tional 10× factor is not needed at all because
the default assumptions used in regulatory
risk assessments already are conservative
enough to account for variation in suscepti-
bility among individuals, including that due
to age (5). Here we evaluate the data and
analyses required to resolve this controversy.
Dividing a cancer potency or a no-
observed-adverse-effect level by 10 to account
for sensitivity due to age implies that a sub-
stance could be up to 10 times more potent,
or more effective at inducing toxicity, in chil-
dren as compared to adults. One of the fun-
damental problems with trying to evaluate
whether the 10× factor is appropriate is that
biology is not so straightforward. Describing a
chemical (or pharmaceutical) as “twice as
potent”or “five times more effective than”
another chemical is simplistic. Few, if any,
chemicals maintain such a constant relation-
ship between dose and response for all levels
of exposure. What toxicologists and pharma-
cists generally understand is that one chemical
can be “twice as potent” as another within a)
a deﬁned, and often relatively limited, range
of doses or responses and b) our ability to
detect a variation from the expected potency,
given that we know individuals will respond
somewhat differently. Thus, such measures of
relative potency are useful, but not strictly
accurate. The concept of relative potency can
be equally useful in toxicology and risk assess-
ment, but the limitations on accuracy, includ-
ing the need to restrict the response range for
the comparison, also apply.
Similarly, the difference in response
between two groups within the general pop-
ulation (e.g., children and adults) will rarely
be the same for all exposures. Consider some
of the potential mechanisms that could
account for a difference in response between
groups. The following are simplistic but
illustrative examples. 
• To produce a response, the chemical must
bind to receptors (in the most general deﬁ-
nition of that term), and the extent of
binding is the critical step in determining
the response. Assume that adults are less
efficient at binding the chemical to the
receptors than children. For a constant
relationship to hold, an adult would have
to bind a constant percentage less than a
child. At the exposure where a child’s
receptors are 100% occupied, increasing
the concentration would increase the
response of an adult, but not of a child.
Similarly, at exposures where an adult binds
(effectively) none of the chemical, a child
could bind 0–10% (if children are 10 times
more sensitive). Given that the difference in
the amount bound by adults and by chil-
dren cannot be a constant for the complete
range of doses, the issue of concern is the
size of the deviation and whether it matters
in the context of the decision to be made.
• The chemical must be metabolized by a
particular form of the enzyme cytochrome
P450 to become biologically active and
produce a response. In adults, the P450 of
concern is inducible, and in children it is
not. The relationship between the child’s
and adult’s formation of the toxic deriva-
tive will be a constant at very low doses
and for a brief period of time at higher
doses until the adult’s P450 is induced.
The rate of formation of the toxic deriva-
tive by the adult will then greatly increase
compared to the child’s, increasing the dif-
ference between the child’s and the adult’s
sensitivities. If the potential difference is
estimated at the higher exposure level, the
child’s risk at a lower level would be sub-
stantially overestimated.
• The mode of action that quantitatively
determines the toxic response is not the same
for all levels of exposure. For example,
dose–response modeling for enzyme- or
receptor-mediated toxicity is often assumed
to be ﬁrst order at low doses. The model fre-
quently used for that assumption (Michaelis-
Menton kinetics or related algorithms)
further assumes that the chemical of concern
is present in quantities signiﬁcantly greater
than the enzyme or receptor. Clearly, this
assumption will be accurate for only higher
levels of exposure. Similarly, the critical or
rate-determining step for the toxic effect,
and hence for the dose–response relation-
ship, may change with dose (6). 
• Two molecules of the chemical must work
together to produce toxicity. For example,
two molecules must bind to a receptor to
produce (maximal) activity, or a dimer
must form to produce the response of con-
cern. (Perhaps the best known example of
multiple sites for ligand interaction with a
receptor is hemoglobin, with its four bind-
ing sites for oxygen.) If two molecules are
necessary to produce a response, the
response is more likely to vary with dose
squared, or with some other nonlinearly
proportional relationship with dose, rather
than dose. The 10× factor implicitly
assumes the response varies in a linearly
proportional relationship with dose.
Because the concept that chemicals’ rela-
tive potencies can be calculated by simply
multiplying by a constant is an approxima-
tion, whether a 10× factor will be sufﬁciently
(or overly) protective depends on the dose at
which the measurement is made compared to
the exposure of interest. Thus, comparison of
the doses required to produce any specified
level of response will only provide informa-
tion regarding that dose, or reasonably simi-
lar doses. Although such information is likely
to be useful for doses near those evaluated,
the information may prove significantly
faulty for doses that are 10- to 100-fold lower
or higher, a significant consideration given
that differences between doses used in the
laboratory and actual human doses often vary
by several orders of magnitude. Evaluating
the appropriateness of a 10× factor for age-
related differences in susceptibility thus
depends on knowing how the dose–response
relationships for children and adults change
with level of exposure.
Age and Susceptibility to
Carcinogenesis
In the context of chemical carcinogenesis,
arguments for and against an additional 10×
factor to account for age-related differences
can be made on both theoretical and experi-
mental grounds. The developing organism
experiences many complex, integrated events
involving the regulation of cell growth, dif-
ferentiation, and morphogenesis. Interfering
with those events through mutation or
through altered mitosis, nucleic acid biosyn-
thesis, membrane function, enzyme func-
tion, or energy sources can have significant
adverse impacts on development (7,8).
Many factors can have an impact on normal
development, including nutrition and folic
acid availability, maternal smoking and alco-
hol consumption, prescription drugs, and
environmental contaminants such as lead
and organic mercury. [For a useful review of
the factors that underlie developmental sus-
ceptibility to environmental toxicants, see
Faustman et al. (7).]
Factors that have an impact on develop-
ment obviously cannot be characterized as a
fractional response of the adult to chemical
carcinogenesis. Many of those responses will
never be observed in the adult, making the
ratio of adult’s to children’s responses zero.
Identifying developmental responses requires
that they be tested for specifically. The in
utero carcinogenic effects of diethylstilbe-
strol, for example, would not have been
detected using standard rodent bioassays, so
neither could it have been identiﬁed nor pre-
vented using a 10×  uncertainty factor. 
Age can have an impact on susceptibility,
specifically to chemical carcinogenesis in
rodents. Pesticides in the Diets of Infants and
Children (1) included a table summarizing the
results of studies that had been performed
through 1983 in which the effects of age on
chemically induced carcinogenesis in rodents
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those results updated to include studies per-
formed since 1983. Both the original and
updated tables indicate that the number of
studies showing that younger animals are less
susceptible than adults (53%) to chemically
induced carcinogenesis is similar to the num-
ber showing that they are more susceptible
(37%) under the conditions of the bioassays
(Figure 1). A number of studies showed that
age played no role at all in susceptibility
(10%). What those results demonstrate is that
it is difficult to make generalizations about
the effect of age on susceptibility to chemical
carcinogens. Age can affect metabolism, cell
proliferation rates, and hormone levels, for
example, which can in turn affect tumor inci-
dence, latency, and tumor type, as can myriad
other interactions that are genetically, behav-
iorally, and environmentally determined. The
National Academy of Sciences report (1) con-
cluded that those results clearly demonstrate
that age may be an important factor in sus-
ceptibility to chemically induced carcinogene-
sis, but they do not support the conclusion
that younger animals are always more suscep-
tible than older animals. This database also
illustrates the difﬁculty associated with assess-
ing the need for a 10× factor to address chil-
dren’s sensitivity. Virtually all of the studies
listed used only one dose level, so the underly-
ing dose–response relationships are unknown,
and comparison of sensitivities is possible
only at the relatively high dose levels used.
Effect of Age on
Dose–Response Relationships
In most cases, chemical carcinogens have the
same mechanism of action in children as in
adults (64). If children are more or less sus-
ceptible than adults, however, the difference
in susceptibility would affect the shape of the
dose–response curve, which is the cumulative
distribution of the responses. Rather than
only considering this cumulative distribution,
examining the distribution itself is instructive
when evaluating the need for an additional
10× factor.
Characterizing the distribution of proba-
bility of a response for additional (or incre-
mental) responders as a function of dose is
important for the usual interpretation of cur-
rent safety or uncertainty factors. Those fac-
tors are said to account for the uncertainty
and/or variability within the human popula-
tion or between the human population and a
test species (65). Various analyses have
examined the variability within the popula-
tion(s) these factors are likely to encompass,
the distribution of the incremental respon-
ders as an indication of that variability, and
the extent to which a safety or uncertainty
factor may overestimate or underestimate
those distributions (2,66).
Normal and log-normal distributions are
often assumed for risk assessment parameters
such as the distribution of the probability of
response for incremental responders. If chil-
dren are best characterized by a different dis-
tribution than adults, then the changes in the
Children’s Health • Children, susceptibility, and risk
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Table 1. Effect of aging on latency, incidence, and size of tumors at different sites.a
Animal Carcinogenic Age group Effect of
Site species agent (months) aging Reference
Skin Mouse MC, BP, TC,  2–4 and 12–13 No effect (9,10)
MC, DMBA 1.5–4 and 12–13 Decrease (10,11)
DMBA 2 and 11 Increase (12)
DMBA 14–20 and 22–24 Increase (13)
UV-light 2–3 and 10 Decrease (14)
Fast neutrons 1–3 and 21 Decrease (15)
Electrons 1 and 13 Decrease (16)
Soft tissues Mouse BP, DBA 1–3 and 6 Increase (17)
MC 6 and 20 Increase (18)
MC 3–4 and 12 Decrease (19,20)
DMBA 2–6 and 13 Increase (12)
Plastic ﬁlms 1 and 15.5 Increase (21)
Moloney sarcoma 3 and 30 Increase (22)
virus
Rat BP, MNU 3–4 and 9–14 Increase (23–25)
Bone Rat Radionuclides 2–3 and 8–10 No effect (26,27)
Mammary gland Rat DMBA, MC Maximal sensitivity (28,29)
at 50 to 75 days
DMBA, MNU 3–4 and 14–16 Decrease (30,31)
FBAA 1–6 and 12 Decrease (32)
Estrogens 1 and 20 Increase (33)
7
5Se-seleno- 3 and 24–26 Increase (34)
methionine
Liver Mouse DMH 2–3 and 12–13 No effect (35)
Rat CCl4 1–6 and 12 Increase (36)
FBAA, DENA, 1–6 and 12 Decrease (32,37,38)
AFB1
DMNA 1.5 and 18 Decrease (39)
Frog DMNA, DMN 2 and 12–18 Increase (40)
Esophagus and Mouse DENA 2.5 and 17 Increase (41)
forestomach
Rat DENA 1–6 and 12 Decrease (42)
Stomach Rat MNNG 1.5–4.5 and 9 Decrease (43)
Colon Mouse DMH 3 and 12 Increase (44,45)
Rat DMH 8–10 and 18 Decrease (46)
2 and 7 Decrease (47)
Pancreas Mouse MNU 3, 12, and 24 Increase (45)
Kidney Rat FBAA, MNU, 1–6 and 12–18 Decrease (31,39,48)
DMNA
Bladder Mouse DMBA (in vitro) 1.5–2 and 28–30 Increase (49)
Lung Mouse DENA 2.5 and 12 Increase (41)
MNU 3 and 24 Increase (45)
DBA, urethane 2.4 and 11–12 Decrease (50)
Rat Fast neutrons 3 and 21 Increase (15)
Pleura Rat Asbestos 2 and 10 Increase (51)
Uterus Mouse DMH 2 and 12 Increase (44)
Rat MNU 3 and 14 Increase (31)
Vagina Mouse DMBA 3 and 18 Increase (24)
Ovary Mouse X-ray 2 and 12 Decrease (52)
Testis Rat Fast neutrons 3 and 21 Increase (15)
Vascular wall Mouse DENA 2.5 and 17 Increase (41)
Rat Vinyl chloride 1.5–4 and 12 Increase (53)
Hematopoietic Mouse X-rays 1–2 and 6 Decrease (54,55)
system MNU 3, 12, and 24 Increase (45)
PMS 6 and 10 No effect (56)
Rat MNU 3 and 14 No effect (31)
Radionuclides 3 and 8–10 Increase (27)
X-rays 4 and 12 Decrease (52)
Frog DMNA, DMN 1.5–2 and 12–18 Decrease (40)
Abbreviations: AFB1, aflatoxin B1; BP, benzo[a]pyrene; DBA, 1,2,5,6-dibenzanthracene; DENA, N-nitrosodiethylamine;
DMBA, 7,12-dimethylbenz[a]anthracene; DMH, 1,2-dimethylhydrazine; DMN, dimethylnitramine; DMNA, N-nitrosodi-
methylamine; FBAA, N-4(fluorobiphenyl)acetamide; MC, 3-methlycholanthrene; MNNG, N-methyl-N-nitro-N-
nitrosoguanidine; MNU, N-nitrosomethylurea; TC, tobacco smoke concentrate. 
aReproduced with permission from Pesticides in the Diets of Infants and Children (1). Copyright 1993 by the National
Academy of Sciences; courtesy of the National Academy Press, Washington, D.C. Reference numbers and deﬁnitions of
abbreviations have been added. characteristic parameters of a distribution
must be known to evaluate whether a 10×
factor is needed. Consider, for example, a
case where the mean (for normal) or median
(for log-normal) of a distribution is the same
for adults and children, but the children’s
distribution is broader; that is, it allows for
more variability and therefore more sensitiv-
ity within the population of children (Figure
2). The relative responses of children and
adults will depend on the response level at
which the comparison is made. Only if the
distributions are truncated at some low level
of exposure would it be possible to state
whether the 10× factor is appropriate for all
exposures above that level. But truncating
exposure assumes a threshold for the effect of
concern, which is often a point of contro-
versy, especially for carcinogenesis. A similar
analysis can be performed by identifying a
response level below which exposures are not
of concern, which would serve as a practical
threshold, established either as a policy
choice or as a response that is undetectable
(for example, a probability of 1 case occur-
ring among 1 million exposed people).
If the width of the distributions for chil-
dren and adults (standard deviation for nor-
mal distributions, or appropriate parameters
for other distributions) is the same, but the
distributions are moved relative to each other
(i.e., the means or other measures of central
tendency differ), it is possible to have a con-
stant relationship between the response of a
child and the response of an adult for any
given exposure (Figure 3). This shift in the
location of the distribution on the axis for
dose would result in a relationship where the
relative sensitivities are constant for all levels
of exposure. Mathematically, this can be
achieved if either the dose–response curves are
straight lines through the origin or the
log(dose)–response curves are parallel. The
former algorithm, an assumption often used
for cancer risk assessment, is assumed only for
doses that produce very low levels of response.
At higher response levels, the dose–response
curves must become curvilinear. The latter
algorithm is assumed for toxic equivalency
factors and some methods for evaluating non-
cancer risks of mixtures (e.g., U.S. EPA’s haz-
ard index), but is based on the pharmacologic
concept of relative potency, the limitations of
which have previously been discussed.
In either case (or in the case where both
the central tendency and width of the distrib-
utions vary), current risk assessment proce-
dures do not provide the appropriate starting
point for evaluating case-by-case needs for a
10× factor to account for age-related differ-
ences in susceptibility. The characteristics of
a distribution require more information than
is available either from potency estimates of
carcinogens or from the point estimates of
acceptable levels of exposure such as accept-
able daily intakes (ADIs) or reference doses
(RfDs) used for noncancer effects. Using
those values as starting points for the applica-
tion of a 10× factor assumes information
about the distributions of the probability of
response for children and adults that is not
knowable from the information provided. To
determine if a 10× factor is appropriate, the
types and characteristics of distributions for
both adults and children must be known for
a sufﬁcient number of chemicals to permit a
reasonable analysis, such as that performed
for other safety/uncertainty factors. Such an
analysis would also require identiﬁcation of a
desired level of protection because comparing
responses, and even determining which age
group is more sensitive, may depend on the
point of comparison. Thus, comparison of
relative sensitivity at any one response level,
whether an ADI, a median effective dose, or a
point of departure for linear extrapolation, is
not sufﬁcient to determine the relative sensi-
tivity for another level of response.
Limitations of Risk
Assessment Methods
Evaluating the effectiveness of a 10× factor
also depends on whether differences between
adults’ and children’s susceptibilities can be
accounted for by current risk assessment
models. For example, if childhood exposure
to a carcinogen leads to a reduced latency
period for the appearance of adult cancer,
that difference cannot be accounted for by
parameters explicitly considered in current
risk assessment algorithms. The usual
method for calculating cancer risk estimates
the incremental increase in risk over the life-
time of the people exposed, but does not
consider when during a lifetime the cancer
occurs. Even when cancer bioassay results
include information that allows a time-to-
tumor analysis of the data, the results are
usually used to estimate only a lifetime cancer
potency factor. Only the lifetime cancer risk,
not the age at which cancer occurs, is evalu-
ated. If the difference in a child’s sensitivity is
due to a change in latency, not to a change in
potency, lifetime cancer risk will appear
unchanged using current regulatory methods
for estimating cancer risks. Need for a 10×
factor to account for that type of change can-
not be evaluated using current methods.
Even if latency were considered, another
question must be answered before the need
for a 10× factor can be assessed: Is the factor
an adjustment of dose so that the latency
period is the same regardless of age at expo-
sure, or so that the disease manifests itself
with the same age distribution regardless of
when the exposure occurs? The former is the
usual hypothesis tested, but even if an addi-
tional 10× factor were applied, the result
would still be an earlier occurrence of cancer
due to the earlier exposure. That is, an addi-
tional 10× factor would not necessarily have
an impact on the age at which cancer occurs.
Thus, the goal of any adjustment for a more
sensitive population should be clear.
A final consideration in evaluating the
need for another 10× factor is the regulatory
use of statistical upper bounds on cancer risk
estimates instead of maximum likelihood
estimates. Even if the 10× factor were found
to be appropriate for the best estimate of the
risk for children, there is no reason to assume
that the upper-bound risks would have the
same relationship as the best estimates. For
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Table 2. Effect of aging on incidence of tumors at different sites: update of Table 1.
Animal Carcinogenic Age group Effect of
Site species agent (months) aging Reference
Thymus Rat N-Propyl-N-nitrosourea 1.25, 2.5, 5, 10 Decrease (57)
Endometrium Mouse Ethylenethiourea and 1, 6, 12 Increase (58)
sodium nitrite
Mammary Rat 7,12-Dimethylbenz(a) 0.3–2, 3, 5, 15 Increase for  (59)
gland anthracene malignant tumors;
decrease for 
benign tumors
N-Nitroso-N-methylurea 1, 2.5, 4.5, 6.5 Decrease (60)
Prostate Rat 3,2’-Dimethyl-4- 1, 9, 16 No effect (61)
aminobiphenyl
Kidney Mouse N-Butyl-N-(4-hydroxybutyl)- 1.5, 4, 11 No effect (62)
nitrosamine
Urinary Rat N-Butyl-N- 1.5, 12, 23 Increase (63)
bladder (4-hydroxybutyl)-nitrosamine
Figure 1. Percentage of total studies performed
evaluating the effect of age on chemical carcino-
genesis in rodents.
Older animals
more susceptible
47%
Younger animals
more susceptible
40%
Age had no effect
13%example, if the linear, no-threshold model for
carcinogenesis were accurate for both the
child and the adult, then it would be mathe-
matically possible to have a constant relation-
ship between the response for the child and
the response for the adult. However, either
the upper-bound dose–response curves could
have this relationship or the true dose–
response curves could have this relationship,
but not both. Assuming that both have this
relationship is to assume that uncertainty
decreases at lower doses, when we know
instead that uncertainty must increase
(67,68). Thus, if the true relationship
between the child and the adult responses
were a constant, the upper-bound risks that
we currently estimate could not have this
relationship. If the upper-bound risks have
this relationship, the actual risks cannot. If
the data indicate that children are more sensi-
tive, this effect should be evaluated in the
regulatory context of the usual upper-bound
risk estimate. Simply adjusting the upper-
bound risk is likely to result in a demonstra-
bly incorrect result based on an artifact of the
method we use to calculate the carcinogenic
risk, not the true toxicologic relationship.
Conclusions
Experimental evidence clearly shows that
young animals are not always more sensitive
than older animals to chemically induced car-
cinogenesis (1). Because the biological modes
of action involved in carcinogenesis are mul-
tiple and varied, many factors may account
for differences in sensitivity. Rates of metabo-
lism and clearance in the young are generally
faster than those in adults, which may
increase or decrease toxicity. For example,
many cytostatic agents must be administered
to children at up to ﬁve times greater doses
on a per body weight basis than the dose to
adults. Although it is true that developing
organisms may be of special sensitivity simply
because they are developing, whether envi-
ronmental contaminants are having a dispro-
portionate impact on the young is a matter
primarily of conjecture (with some obvious
exceptions, such as lead). However, much is
known about the special sensitivity of the
elderly to pharmacologic agents (69), and the
elderly have also been viewed as a population
at special risk from environmental insult due
to their enhanced sensitivity (70). An argu-
ment could be made on that basis that an
extra 10× factor is needed to protect the
elderly as well as the young. 
It is possible to identify many people
within the general population who may have
greater sensitivity to some chemicals. Indeed,
any life stage or group that is identiﬁed based
on physiologic or pharmacologic parameters
would be expected to have some greater and
lesser sensitivities than the general population.
Current risk assessment procedures account
for at least some of this variability, and the
extent to which they already protect a life
stage or group should be examined as part of
any quantitative analysis of the need for addi-
tional safety factors. Requiring additional fac-
tors for all possible groups with special
sensitivities would likely result in restrictions
on exposure without additional protection of
public health (71).
For those cases in which a different mech-
anism causes the toxicity in one group, such
as developmental effects in utero, no scientiﬁc
method is available to estimate the effect
quantitatively based on another toxic effect.
The effect-speciﬁc experiments must be per-
formed. In those cases in which the mecha-
nism of toxicity is assumed to be the same
among groups, information on the distribu-
tion of probability of response—not on just
one response level—is required to determine
the relative potencies for exposures of interest.
If an uncertainty or safety factor is desired for
general use in evaluating chemicals, a particu-
lar response level to be evaluated must be
selected because the distribution of relative
potencies varies with response levels.
Standard risk management practice
based on regulatory risk assessment allows
reductions in permissible exposures using
uncertainty factors when data considered
critical (based on type of chemical or its
intended use) are not available. Determining
which data are critical usually includes policy
considerations as well as toxicology.
Selecting the size of an uncertainty factor is
usually pragmatic rather than scientific: 10
and 3 (considered a reasonable approxima-
tion of half a log unit) are the most common
values, with occasional use of 5 or 2.
Approximations abound. When distribu-
tions in variability have been examined, the
values are rounded up to an order of magni-
tude. Adding another uncertainty factor to
those approximations is possible, but must
be viewed as a policy-driven approximation,
not a scientiﬁcally derived value.
The potential beneﬁts and drawbacks of
using an additional 10× uncertainty factor to
account for potentially greater susceptibility
of children to chemicals should be weighed
carefully. Application of the precautionary
principle in the absence of a risk analysis
framework would support the need for an
additional factor where data on sensitivity are
unavailable because, although experimental
evidence suggests that young animals are
more sensitive to chemically induced carcino-
genesis about half the time, it is appropriate
to err on the side of caution. Application of
the precautionary principle within a risk
analysis framework would involve weighing
the costs of more stringent standards, consid-
ering the risks of substitutes, and determining
the beneﬁts of a 10× factor which, as we have
demonstrated, cannot be evaluated without
far more information than is currently avail-
able. It therefore remains unclear whether
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Figure 2. Effect of differences in variability in sensitivity on the distribution of probability of response as a
function of dose when the population means are the same. The solid line (adults) has less variability than
the dotted line (children); distributions are assumed to be normal. (A) Probability distribution of additional,
or incremental, responders as a function of dose. (B) Probability of response as a cumulative distribution
(i.e., dose–response curve). 
Figure 3. Effect of differences in population mean on the distribution of probability of response as a func-
tion of dose when variability in sensitivity is the same for both populations. The solid line (adults) has a
lower mean than the dotted line (children); distributions are assumed to be normal. (A) Probability distrib-
ution of additional, or incremental, responders as a function of dose. (B) Probability of response as a
cumulative distribution (i.e., dose–response curve).
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emaking regulation of chemical exposures 10
times more stringent will demonstrably
improve public health in general or children’s
health in particular. Without a clearer
demonstration of the beneﬁts of greater strin-
gency, whether and to what extent adding
another 10× uncertainty factor to risk deci-
sions will have the effect of protecting or
improving children’s health is unknown.
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